Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Revised Hospital Accreditation Standards in Lebanon- December 2022

 
The health care system has been adversely impacted by multi-dimensional crisis, including the economic collapse, COVID-19 pandemic, Beirut Port explosion, and socio-political unrest. The unavailability and increased cost of basic commodities such as fuel and electricity has further challenged an overburdened system.

Maintaining the quality of care and patient safety in the midst of the challenges facing health institutions remains a priority and constitutes a guarantee for quality services. Maintaining quality standards saves lives, contributes to alleviating the financial burden, and reserves the position of high-level health services on the health map in the region.

After a long period of pausing the Accreditation process in Lebanon, the Ministry of Public Health is working again to revive this very important project that has started since 2001 and was updated and improved over time.  For the purpose of improving and updating the current hospital accreditation system in Lebanon, the Ministry of Public Health aimed to revise and develop new Lebanese hospital accreditation standards according to latest evidence and international best practices, in compliance with International Society for Quality in Healthcare (ISQua) requirements.

Since January 2022, and under the great support of AFD (Agence Française de Développement), a cooperation agreement was signed between the Lebanese Ministry of Public Health (MOPH) and the French Health Authority (HAS) for a new iteration of the accreditation project in collaboration, in collaboration with the Ecole Supérieure des Affaires (ESA) as a local counterpart to ensure logistical, educational and administrative support. The governance of the program kept the current organizational structure: the Comité National d’Accréditation Hospitalière (CNAH) and the Comité Technique d’Accréditation Hospitalière (CTAH). In addition to a new unit created at the Ministry of Health as the operational structure, the Bureau d’Accréditation et d’Evaluation (BAE) to follow-up on the implementation of the project. The revision of the procedure and the manual was performed by local and international experts.

The Ministry of Public Health announces the official publication of the new accreditation standards manual for hospitals. The present version has been updated to include “intent”  sections for each standard, aiming at allowing hospitals better comprehend and meet the requirements of the standards.

For any inquiry, please contact the Accreditation office at the MOPH by email on:
accreditation@moph.gov.lb or ritafreiha@hotmail.com
 
    ...
    9
    ...
ATC Name B/G Ingredients Dosage Form Price
A06AX01 SUPPOSITOIRE GLYCERINE ADULTE G Glycerol Stearate USP - Suppository 179,179 L.L
C10AA07 SUPERSTAT G Rosuvastatin (calcium) - 10mg 10mg Tablet, coated 517,379 L.L
N02BE51 SOLPEX G Paracetamol - 500mg, Caffeine - 30mg, Codeine - 8mg Tablet 243,172 L.L
J01DD01 STOPAREN G Cefotaxime (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 213,671 L.L
J01RA SPIRAGYL G Metronidazole - 125mg, Spiramycin - 750,000IU Tablet, scored 474,824 L.L
N05AH04 SEROPINE 25 G Quetiapine fumarate - 25mg 25mg Tablet, film coated 1,233,647 L.L
J01RA SPIRAGYL FORTE G Metronidazole - 250mg, Spiramycin - 1,500,000IU Tablet, scored 474,824 L.L
L04AC05 STELARA BioTech Ustekinumab - 45mg 45mg Injectable solution 143,682,251 L.L
L04AC05 STELARA BioTech Ustekinumab - 90mg 90mg Injectable solution 143,682,251 L.L
L04AC05 STELARA BioTech Ustekinumab - 130mg 130mg Injectable concentrate for solution 214,532,009 L.L
L04AC18 SKYRIZI BioTech Risankizumab - 75mg 75mg Injectable solution 194,911,251 L.L
L04AC18 SKYRIZI BioTech Risankizumab - 150mg 150mg Injectable solution 194,911,251 L.L
L01FG01 STIVANT BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 27,359,527 L.L
L01FG01 STIVANT BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrate for solution 14,719,570 L.L
L01XX02 SPECTRILA BioTech Asparaginase, recombinant - 10,000IU 10,000IU Injectable powder for concentrate for solution 21,370,813 L.L
A10AE54 SULIQUA BioTech Insulin glargine - 100IU/ml, Lixisenatide - 50mcg/ml Injectable solution 11,286,573 L.L
A10AE54 SULIQUA BioTech Insulin glargine - 100IU/ml, Lixisenatide - 33mcg/ml Injectable solution 7,975,793 L.L
L04AC05 STELARA BioTech Ustekinumab - 90mg 90mg Injectable solution L.L
J06BD01 SYNAGIS BioTech Palivizumab - 100mg/ml 100mg/ml Injectable solution 57,429,464 L.L
J06BD01 SYNAGIS BioTech Palivizumab - 50mg/0.5ml 50mg/0.5ml Injectable solution 38,316,693 L.L
L04AB06 SIMPONI BioTech Golimumab - 50mg/0.5ml 50mg/0.5ml Injectable solution 68,840,586 L.L
A10BJ02 SAXENDA BioTech Liraglutide - 6mg/ml 6mg/ml Injectable solution 19,709,575 L.L
L04AB06 SIMPONI BioTech Golimumab - 100mg/1ml 100mg/1ml Injectable solution 68,840,586 L.L
L04AC02 SIMULECT BioTech Basiliximab - 20mg 20mg Injectable powder + solvent 120,805,978 L.L
G04CA04 SILOSIN B Silodosine - 4mg 4mg Capsule 1,251,693 L.L
R03DC03 SINGULAIR PAEDIATRIC B Montelukast (sodium) - 4mg 4mg Granules 1,248,430 L.L
G04CA04 SILOSIN B Silodosine - 8mg 8mg Capsule 1,927,454 L.L
A07BC05 SMECTALIA B Diosmectite - 3g/sachet 3g/sachet Powder for suspension 935,570 L.L
A07BC05 SMECTALIA STRAWBERRY B Diosmectite - 3g/sachet 3g/sachet Powder for suspension 935,570 L.L
D10AX03 SKINOREN B Azelaic acid - 0.2g/g 0.2g/g Cream 722,987 L.L
    ...
    9
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025